Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
Publication
, Conference
Hoimes, CJ; Loriot, Y; Bedke, J; Nishiyama, H; Kataria, RS; Moreno, BH; Galsky, MD
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hoimes, C. J., Loriot, Y., Bedke, J., Nishiyama, H., Kataria, R. S., Moreno, B. H., & Galsky, M. D. (2023). Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Hoimes, Christopher J., Yohann Loriot, Jens Bedke, Hiroyuki Nishiyama, Ritesh S. Kataria, Blanca Homet Moreno, and Matt D. Galsky. “Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Hoimes CJ, Loriot Y, Bedke J, Nishiyama H, Kataria RS, Moreno BH, et al. Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Hoimes, Christopher J., et al. “Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.
Hoimes CJ, Loriot Y, Bedke J, Nishiyama H, Kataria RS, Moreno BH, Galsky MD. Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences